Publication Name	World Journal of Diabetes
Manuscript ID	13178
Country	Cyprus

Received	2014-08-09 21:00
Peer-Review Started	2014-08-11 08:37
To Make the First Decision	2014-08-28 15:04
Return for Revision	2014-08-30 15:14
Revised	2014-09-10 01:57
Second Decision	2014-11-10 15:41
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-11-10 16:00
Articles in Press	2014-11-10 16:00
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-11-28 15:50
Publish the Manuscript Online	2014-12-13 19:01

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Review
Article Title	Incretin-based therapies in prediabetes: Current evidence and future perspectives
Manuscript Source	Invited Manuscript
All Author List	Georgios S Papaetis
Funding Agency and Grant Number
Corresponding Author	Georgios S Papaetis, MD, PhD, Internal Medicine and Diabetes Clinic, Eleftherios Venizelos Avenue 62, Paphos 8049, Cyprus. gpapaetis@yahoo.gr
Key Words	Type 2 diabetes; Prediabetes; Impaired fasting glucose; Impaired glucose tolerance; Glucagon-like peptide-1; Dipeptidyl peptidase-4 inhibitors; Glucagon-like peptide-1 receptor agonists
Core Tip	The beneficial effects of incretin-based therapies on β-cell function in patients with type 2 diabetes (T2D) suggested their possible use in individuals with prediabetes, when greater β-cell mass and function are preserved. Both dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists have demonstrated improvements on β-cell function both in preclinical studies and short-term clinical studies. Until future date for their safety are available, large, long term, prevention trials will be required in order to determine whether they can stabilize or reverse β-cell loss and promote a sustained reduction in the development of T2D in this population.
Publish Date	2014-12-13 19:01
Citation	Papaetis GS. Incretin-based therapies in prediabetes: Current evidence and future perspectives. World J Diabetes 2014; 5(6): 817-834
URL	http://www.wjgnet.com/1948-9358/full/v5/i6/817.htm
DOI	http://dx.doi.org/10.4239/wjd.v5.i6.817

Full Article (PDF)	WJD-5-817.pdf
Full Article (Word)	WJD-5-817.doc
Manuscript File	13178-Review.docx
Answering Reviewers	13178-Answering reviewers.pdf
Copyright License Agreement	13178-Copyright assignment.pdf
Peer-review Report	13178-Peer review(s).pdf
Scientific Misconduct Check	13178-CrossCheck.jpg
Scientific Editor Work List	13178-Scientific editor work list.pdf